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A three-dimensional model of PTTH-II has been constructed using interactive computer graphics and ener- 
gy minimisation techniques, assuming homology with porcine insulin, the structure of which has been 
determined by X-ray analysis. The model shows that PTTH-II can assume an insulin-like tertiary structure, 
which is compact with the exception of the sequence variable NH,-terminal amino acids of the B chain. 
Most of the hydrophobic core residues including A2 Be, A6 Cys, Al 1 Cys, Al6 Leu, A20 Cys, Bll Leu, 
B15 Leu and B19 Cys are identical in PTTH-II and insulins. The glycines at Al, B8 and B23 allow the chain 
to assume the characteristic tertiary interactions of the insulin fold and although polypeptide chains are 
shorter at the COOH-termini of the A and B chains and extended at the NH,-terminus of the B chain, 
the insulin-like tertiary structure can still be assumed. It is unlikely that PTTH-II forms either dimers or 
hexamers, characteristic of porcine and human insulin, and the model is consistent with the inability of 
PTTH-II to bind anti-insulin antibodies or insulin receptors. A hydrophobic surface region of PTTH-II may 
be involved in intermolecular actions of physiological relevance. We discuss the implications of our model 
for evolution of this family of hormones and growth factors. 
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1. INTRODUCTION 
Prothoracicotrophic hormone (PTTH) is se- 
creted by the brain of the silkworm, Bombyx mori, 
and acts on the prothoracic glands to stimulate the 
release of ecdysone [1,2]. B. mori contains two 
kinds of PTTH, a low molecular mass (4400 kDa) 
and a high molecular mass (22 kDa) species. 
Recently the 4 kDa-PTTH has been shown to be 
heterogeneous and to contain several species which 
differ in sequence [3]. The sequence of one of 
these, PTTH-II, has now been published [4] and 
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has been shown to have two chains with 40% 
homology with the A and B chains of human in- 
sulin. More recently, several more sequences have 
become available which also have a high degree of 
homology with insulin. The homology suggests 
that PTTH is a member of the insulin family of 
hormones and that it is reasonable to assume an 
insulin-like tertiary structure. Most strikingly the 
hydrophobic core residues - A2 Ile, A6 Cys, Al 1 
Cys, Al6 Leu, A20 Cys, Bll Leu, B15 Leu and 
B19 Cys - are identical in PTTH-II and insulins. 
The shorter COOH-terminus of the B chain that is 
more reminiscent of relaxin, does not prevent the 
assumption of an insulin-like tertiary structure 
[7-lo], but it is unlikely that PTTH-II forms either 
dimers or hexamers, characteristic of porcine and 
human insulins [5,6]. The model is consistent with 
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the inability of insulin to evoke PTTH activity. A 
hydrophobic surface region of PTTH-II may be in- 
volved in intermolecular interactions of physiolog- 
ical relevance. 
2. MATERIALS AND METHODS 
The sequence of PTTH-II was aligned with the 
known sequences of insulins, insulin-like growth 
factors and relaxins (see [5] for a review) and the 
identical and conservatively varied residues iden- 
tified. The aligned sequence of PTTH-II was 
modelled using the program FRODO [l l] on to the 
three-dimensional structure of insulin [6]. Identical 
residues were given the same coordinates. The side 
chains of conservatively varied residues were 
placed so that side chain torsion angles were 
similar to those of the residues replaced and oc- 
cupied the same region of space where this was 
compatible with good intramolecular interactions. 
Where there were more radical sequence dif- 
ferences and at chain extensions, main chain tor- 
sion angles were made consistent with secondary 
structure prediction, the maintenance of good ter- 
tiary interactions or similar supersecondary struc- 
tures [ 12,131. The structure was energy-minimised 
and analysed using programs developed by Dr I. 
Haneef and A. Hemmings at Birkbeck (Haneef, 
unpublished results; [14]) which use the functions 
of Weiner et al. [15]. 
3. RESULTS AND DISCUSSION 
Table 1 shows the alignment of the PTTH se- 
quences with the insulin, insulin-like growth factor 
and relaxin sequences (see [ 161 for review). PTTH- 
II has the arrangement of half-cystines that is 
characteristic of the insulin family. PTTH-II and 
PTTH-V also have glycines that are found in all in- 
sulins at B8 and B23, although in PTTH-IV B23 is 
serine. In insulins, these residues have torsion 
angles in which 4 is positive [5,6], a conformation 
which is only easily available to glycine that has no 
side chain. B8 Gly enables the main-chain to turn 
sharply after the cystine at B7 to form the a-helix 
between B9 and B19. A further chain reversal be- 
tween B20 and B23 involves sharp turns at B20 and 
B23. In most insulins B20 is glycine but this is not 
the case in many hystricomorph insulins such as 
those of guinea pig, coypu, casiragua and cuis 
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[ 17-211. It has been suggested that these isulins 
may not have the type II turn [22] between B19 and 
B21 with a hydrogen bond from B19 CO to B22 
NH, but rather a type I or III turn where B20 has 
a torsion angle allowed for a residue with a side 
chain. It is thus possible to model the main chain 
of PTTH-II with a conformation close to that of 
human insulin, and in an identical way to that of 
the modelled structures of hystricomorph insulins 
with such’s type III turn between B19 and B22 
(fig.la,b). Apart from the substitution of valine 
for isoleucine at B2 in PTTH-IV, all the changes in 
sequence variant PTTHs affect surface residues. 
These side chain substitutions can be easily accom- 
modated in the modelled structure for PTTH-II 
except for the substitution of serine for glycine at 
B23 in PTTH-IV which creates some difficulty in 
modelling the C- terminal portion of the B chain. 
It is possible that this portion of the molecule 
deviates from the insulin structure and that the C- 
terminus of the B chain of the PTTHs is more flex- 
ible than the insulin B chain. 
Al Gly appears to be conserved to enable the 
helix A2-A8 to pack into the tertiary structure, 
and this glycine is also found in the PTTHs. The 
other residues in the A chain of PTTH-II are con- 
sistent with an insulin-like conformation, as shown 
in fig.lc and d. In insulin, the interchain di- 
sulphides of cystines A7-B7 and A20-B19 lead to 
a globular structure with a hydrophobic core. Cen- 
tral to this core are hydrophobic residues A2 Ile, 
A6 Cys, All Cys, Al6 Leu, A20 Cys, Bll Leu, 
B15 Leu and B19 Cys. These are all conserved in 
the PTTH sequences except for the conservative 
substitution of Val for Be in PTTH-IV. Other 
residues uch as A3 Val (Val in PTTH-II), Al9 Tyr 
(Tyr), B6 Leu (Tyr), B6 Leu (Tyr), B12 Val (Ala), 
B18 Val (Leu), B24 Phe (Val), contribute to the 
hydrophobic core although they are on the surface 
of the insulin protomer; they are all conserved as 
hydrophobic in PTTH and modelling shows that 
they are compatible with an insulin-like tertiary 
structure. Thus PTTH could form a tertiary struc- 
ture with a hydrophobic core similar to all known 
insulins including those of the hagfish [23], the pig 
and the human [5,24] which have been defined by 
X-ray analysis. The proposed tertiary structure of 
PTTH-II is shown in fig.le. 
The absence of a residue equivalent o A21 of in- 
sulin and insulin-like growth factors would not 
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prevent the formation of an insulin-like fold 
although it might destabilise it. In mammalian in- 
sulins, removal of the A21 Asn and B30 Ala leads 
to changes in conformation as measured by cir- 
cular dichroism [25]. These are similar to changes 
observed on dilution of native insulin which have 
been interpreted as being due to a reduction in the 
dimer content of an insulin solution [ 181. There is 
strong evidence that dissociation of dimers causes 
changes in circular dichroism consistent with those 
observed for desAla desAsn insulin; there is no 
clear evidence for a difference in three-dimensional 
structure between this analogue and native insulin. 
They may also arise partly from rearrangement of 
B22 Arg which forms an ion pair with A21 a- 
carboxylate and may move to form a similar in- 
teraction with the new carboxylate at A20. In 
PTTH-II the B22 Arg is replaced by alanine and so 
this would not occur. A similar lack of a residue 
equivalent to A21 occurs in relaxins (see Table 1) 
which also lack the arginine at B22 [7-10,261. 
The B chain COOH-terminus of PTTH-II ter- 
minates at B25 and thus is shorter than that of in- 
sulins. Evidence that only small conformational 
changes might occur is found in the extensive 
chemical, biological, spectroscopic and crystallo- 
graphic studies [27,28] of despentapeptide (B25- 
B30)-insulin, which show that this modified insulin 
has an insulin-like conformation and biological ac- 
tivity. 
The B chain NHz-terminus is extended by three 
residues compared to human insulin in a similar 
way to that of relaxin. However, with the excep- 
tion of B3 pyro-glutamic acid in both PTTH and 
relaxin, there is little homology between any of the 
sequences. In insulin this region has an extended 
conformation in 2-Zn crystals which contain a hex- 
amer [5]. The sequences of the region B 1 -B5 are 
very variable between insulins of different species. 
In a similar way, the sequences of four PTTH B 
chain NHz-termini show variation in both se- 
quence and length in this region. We have mod- 
elled the B chain NHz-terminus of PTTH-II with a 
generally extended conformation. However, 
secondary structure prediction [29] of the B chain 
NHz-terminus shows that an a-helical conforma- 
tion might occur as suggested for rat relaxin B 
chain NHz-terminus [30]. 
In summary it appears that the PTTH-II mole- 
cule can have a compact globular structure with 
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the exception of the variable and flexible B chain 
NHz-terminus. If this is so, we can now ask ques- 
tions concerning the arrangement of the surface 
residues. Do they give clues to formation of 
oligomers, antigenicity and receptor binding? 
Let us first consider dimers, which in most mam- 
malian, avian, fish and cyclostome insulins are 
stabilised both by hydrogen bonds and hydro- 
phobic interactions [ 161. The absence of 826 in 
PTTH-II makes this impossible as is shown by 
despentapeptide (B25-B30)insulin which forms 
only monomers [32,33]. The four negatively- 
charged carboxylates from B25 Asp and the 
COOH-termini of the two molecules clustered 
around the dyad would also destabilise a dimer 
similar to that of insulin. 
It is fascinating that BlO is histidine in PTTH-II. 
In most insulins this binds zinc in 2 Zn-hexamers. 
However, zinc binding is unlikely to be strong in 
the absence of hexamers and its existence in PTTH 
is probably an example of convergent evolution as 
both hagfish insulin, the most primitive vertebrate 
insulin sequenced, and insulin-like growth factors 
have no histidine at BlO. 
The remaining surface of insulin is characterised 
by mainly hydrophilic residues. The region involv- 
ing A8-A10 is particularly variable in insulins and 
together with B2, B3 and B4 forms the main non- 
contiguous epitope for antibodies to human or 
porcine insulin raised in rabbits or guinea pigs. 
A&A10 of PTTH is also variable but is different 
from human or bovine insulins. As it is probably 
less flexible due to the proline at AlO, it is not sur- 
prising that PTTH-II does not bind antibodies 
raised in guinea pigs to porcine insulin [3]. 
There has been some debate about the exact ex- 
tent of the insulin receptor binding region although 
it is generally recognised to involve non-continu- 
ous regions of the B chain (B23-B26, B12-B16) and 
A chain (Al, A5, A19-A21) in a surface region 
centred on B25 Phe. The arrangement of this 
region is dependent on maintenance of the tertiary 
structure of insulin. It involves hydrophobic 
residues and main-chain hydrogen bonding func- 
tions surrounded by more polar and charged 
residues. The nature of almost the whole of this 
surface region differs in PTTH-II. In particular, 
the absence of the central, hydrophobic phenyl- 
alanine at B25 would also be expected to reduce 
binding to insulin receptors. 
Volume 219, number 2 FEBS LETTERS July 1987 
b )_ 
Fig. 1. The proposed conformation (a) of the PTTH-II B chain based on the conformation of the porcine insulin B chain 
(b) defined by X-ray analysis [5,6]. Note the amphipatic nature of the cY-helic (B9-B19) and the conservation of glycines 
at B8 and B23 to allow turns in the main-chain. (c) of the PTTH-II A chain based on the conformation of the porcine 
insulin A chain (d) defined by X-ray analysis and (e) a stereo view of the proposed model of PTTH-II. 
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One striking feature of the PTTH-II molecular 
surface demonstrated by our model is an extensive 
hydrophobic surface involving Al3 Val (Leu), Al5 
Val (Gin), Al7 Leu (Glu) and B18 Leu (Val). It has 
been suggested that a similar patch in insulin-like 
growth factors is involved in binding a carrier pro- 
tein. In a similar way the surface hydrophobic 
region of PTTH-II may be important in binding 
other proteins, in the formation of oligomers or in 
receptor binding, but confirmation of this must 
await structure function studies by chemical 
modification, peptide synthesis or site specific 
mutagenesis. 
The fact that PTTH-II almost certainly has an 
insulin-like tertiary structure is strong evidence for 
divergent evolution. An ancestral protein of in- 
sulin, insulin-like growth factor, relaxin and 
PTTH appears to have had at least an insulin-like 
fold of residues equivalent to Al-A20 and B4-B23, 
three disulphide bridges (A7-B7, A6-All and 
B19-A20) and a hydrophobic core of a volume 
similar to that of insulin. In all members of the 
family A2, A16, A19, B6, Bll, B12, B15 and B18 
are hydrophobic and together with the disulphides 
at A6-All and B19-A20 make up the core. Apart 
from the cystines only B8 Gly is invariant, 
probably for maintenance of conformation as 
outlined above. An insulin-like tertiary structure, 
is strong evidence for the existence of a single- 
chain precursor for PTTH. The single-chain 
precursors proinsulin and prorelaxin are well 
established and the tertiary structure of PTTH-II 
would not be expected to form in the absence of 
such a precursor. The existence of a two-chain 
insulin-like molecule in insects strongly suggests 
that the processing of the precursor evolved at an 
early stage, before the divergence of protostomes 
and deuterostomes, and that the loss of processing 
in the insulin-like growth factors I and II could 
have occurred at a fairly recent stage in prever- 
tebrate deuterostomian evolution. 
In many ways PTTH-II is intermediate between 
relaxins and insulins/insulin-like growth factors. 
PTTH-II resembles relaxins in the shorter COOH- 
termini of the A and B chains and the extension at 
the B chain NH2-terminus. It resembles insulin in 
the terminus of the A chain both in length and se- 
quence; there are 18 sequence identities between 
human insulin and PTTH-II, compared with only 
11 between porcine relaxin and PTTH-II. Apart 
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from residues with a structural role, Al2 Ser and 
B21 Glu are conserved on the surface of PTTH-II 
and most insulins, although A12 appears to be 
threonine in PTTH-I and -111 [3]. In a similar way 
B9 Arg and B 13 Arg are conserved in PTTH-II and 
relaxins for reasons which are not presently 
understood. 
The ancestral molecule of the insulin family ap- 
pears to have been monomeric. This is not surpris- 
ing as insulins are active at their receptors as 
monomers (see discussion in [5,16]). The most 
primitive insulin sequenced, that of the hagfish 
[23] is a dimer and modelling indicates that insulin- 
like growth factors may also form dimers [34]. 
Thus the ability to form dimers must have evolved 
at a prevertebrate stage. The formation of hex- 
amers is a vertebrate phenomenon which appeared 
first in the elasmobranch insulins (and is lost in 
some mammalian insulins [35]). 
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